News about "Cipla"

Pfizer Reaches Three Settlement Deals for VYNDAMAX

Pfizer reaches three settlement agreements for VYNDAMAX, extending US patent exclusivity to June 1, 2031, subject to the outcome of other litigation.

Cipla | 30/04/2026 | By News Bureau |  160

Cipla Launches Saxenda for Weight Management

Cipla has strengthened its US portfolio with the launch of a generic version of Saxenda (liraglutide injection), indicated for chronic weight management. The launch follows ANDA approval from the US Food and Drug Administration (FDA), granted to its partner Orbicular, paving the way for expanded access to a more affordable GLP-1 therapy in the US.

Cipla | 02/03/2026 | By News Bureau |  157

Pfizer and Cipla Form Exclusive Marketing Partnership for Select Brands in India

Pfizer and Cipla have joined forces in an exclusive marketing and distribution agreement for select brands in India. The collaboration aims to improve access and availability of these key medicines, ensuring patients across the country benefit from a wider reach and streamlined supply.

Cipla | 19/12/2025 | By News Bureau |  189

Cipla Partners with Stempeutics, Launches Stem Cell Therapy for Knee Osteoarthritis

Cipla has partnered with Stempeutics to launch Ciplostem, a single-dose stem cell therapy for knee osteoarthritis. The treatment uses 25 million expanded Bone Marrow–derived Mesenchymal Stem Cells (BM-MSCs) combined with hyaluronic acid to support joint repair and pain relief.

Cipla | 04/12/2025 | By Dineshwori |  182

Cipla Launches India's First Dedicated Lung Health Diagnostics Centre in Delhi

Cipla has opened the country’s first dedicated lung diagnostics centre in Delhi, equipped to conduct over 60 tests across respiratory function, microbial studies, immune profiling, blood chemistry and imaging.

Cipla | 29/11/2025 | By Dineshwori |  161

Cipla to Acquire Inzpera Healthsciences for INR 110 Crore

Cipla Limited has announced that it will acquire a 100 percent stake in Inzpera Healthsciences Limited for a total consideration of approximately INR 110 crore.

Cipla | 05/11/2025 | By Darshana |  358

Cipla Elevates Achin Gupta as Next Managing Director and Global CEO

Cipla has announced the elevation of Achin Gupta as its next Managing Director and Global Chief Executive Officer, effective April 1, 2026. Currently serving as the company’s Global Chief Operating Officer, Gupta will take over from Umang Vohra, who will step down upon completion of his term on March 31, 2026.

Cipla | 30/10/2025 | By Dineshwori |  368

Kemwell Biopharma's Bengaluru Facility Secures US FDA Clearance for Commercial Manufacturing of Injectable Products

Kemwell Biopharma’s drug-product manufacturing facility in Bengaluru has received clearance from the US Food and Drug Administration (FDA) for the commercial manufacturing and testing of injectable products intended for the US market, following the successful completion of a pre-approval inspection (PAI).

Cipla | 29/10/2025 | By Dineshwori |  400

Eli Lilly And Cipla Partner to Distribute Yurpeak (Tirzepatide) in India

Eli Lilly and Cipla have signed an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak.

Cipla | 27/10/2025 | By Dineshwori |  572

Bora Biologics Partners with Cipla Subsidiary to Manufacture NYPOZI at San Diego Facility

Bora Biologics has partnered with InvaGen Pharmaceuticals, a wholly owned subsidiary of Cipla Ltd., for the manufacture of NYPOZI at its FDA-registered facility in San Diego, California.

Cipla | 29/09/2025 | By Dineshwori |  326